Xarelto Regulatory Post-Marketing Surveillance.

Trial Profile

Xarelto Regulatory Post-Marketing Surveillance.

Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Fondaparinux sodium; Low molecular weight heparins; Vitamin K antagonists
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 16 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top